Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

NCT02448329 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric Adenocarcinoma

Interventions

DRUG: AZD1775
DRUG: paclitaxel

Sponsor

Samsung Medical Center